Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
4999 | 1620 | 30.0 | 48% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | REDUCED HALOPERIDOL | Author keyword | 53 | 78% | 2% | 35 |
2 | BROMPERIDOL | Author keyword | 35 | 76% | 2% | 25 |
3 | REDUCED BROMPERIDOL | Author keyword | 14 | 100% | 0% | 7 |
4 | SCHIZOPHRENIA DRUG THERAPY | Author keyword | 8 | 44% | 1% | 14 |
5 | HPTP | Author keyword | 6 | 80% | 0% | 4 |
6 | FLUPHENAZINE DECANOATE | Author keyword | 6 | 50% | 0% | 8 |
7 | HALOPERIDOL DECANOATE | Author keyword | 5 | 38% | 1% | 10 |
8 | BASIC METABOLITE | Author keyword | 4 | 75% | 0% | 3 |
9 | ANTIPSYCHOTIC AGENTS THERAPEUTIC USE | Author keyword | 4 | 35% | 1% | 9 |
10 | BENPERIDOL | Author keyword | 3 | 57% | 0% | 4 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | REDUCED HALOPERIDOL | 53 | 78% | 2% | 35 | Search REDUCED+HALOPERIDOL | Search REDUCED+HALOPERIDOL |
2 | BROMPERIDOL | 35 | 76% | 2% | 25 | Search BROMPERIDOL | Search BROMPERIDOL |
3 | REDUCED BROMPERIDOL | 14 | 100% | 0% | 7 | Search REDUCED+BROMPERIDOL | Search REDUCED+BROMPERIDOL |
4 | SCHIZOPHRENIA DRUG THERAPY | 8 | 44% | 1% | 14 | Search SCHIZOPHRENIA+DRUG+THERAPY | Search SCHIZOPHRENIA+DRUG+THERAPY |
5 | HPTP | 6 | 80% | 0% | 4 | Search HPTP | Search HPTP |
6 | FLUPHENAZINE DECANOATE | 6 | 50% | 0% | 8 | Search FLUPHENAZINE+DECANOATE | Search FLUPHENAZINE+DECANOATE |
7 | HALOPERIDOL DECANOATE | 5 | 38% | 1% | 10 | Search HALOPERIDOL+DECANOATE | Search HALOPERIDOL+DECANOATE |
8 | BASIC METABOLITE | 4 | 75% | 0% | 3 | Search BASIC+METABOLITE | Search BASIC+METABOLITE |
9 | ANTIPSYCHOTIC AGENTS THERAPEUTIC USE | 4 | 35% | 1% | 9 | Search ANTIPSYCHOTIC+AGENTS+THERAPEUTIC+USE | Search ANTIPSYCHOTIC+AGENTS+THERAPEUTIC+USE |
10 | BENPERIDOL | 3 | 57% | 0% | 4 | Search BENPERIDOL | Search BENPERIDOL |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | REDUCED HALOPERIDOL | 44 | 46% | 5% | 73 |
2 | BUTYROPHENONES | 38 | 93% | 1% | 14 |
3 | PLASMA HALOPERIDOL | 36 | 83% | 1% | 20 |
4 | VISCOLEO | 26 | 100% | 1% | 11 |
5 | FLUPHENAZINE DECANOATE | 22 | 34% | 3% | 53 |
6 | PLASMA HALOPERIDOL LEVELS | 19 | 61% | 1% | 20 |
7 | DEBRISOQUINE HYDROXYLATION PHENOTYPE | 18 | 48% | 2% | 27 |
8 | NEUROTOXIC PYRIDINIUM METABOLITE | 17 | 48% | 2% | 26 |
9 | FLUPHENAZINE | 17 | 28% | 3% | 50 |
10 | INTERMITTENT NEUROLEPTIC PROPHYLAXIS | 16 | 54% | 1% | 20 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
SIGNIFICANCE OF NEUROLEPTIC DOSE AND PLASMA-LEVEL IN THE PHARMACOLOGICAL TREATMENT OF PSYCHOSES | 1988 | 408 | 62 | 77% |
The relationship between serum concentration and therapeutic effect of haloperidol in patients | 1998 | 46 | 87 | 78% |
Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review | 2009 | 29 | 55 | 51% |
Intramuscular preparations of antipsychotics - Uses and relevance in clinical practice | 2003 | 59 | 80 | 41% |
NEUROLEPTIC WITHDRAWAL IN SCHIZOPHRENIC-PATIENTS - A REVIEW OF THE LITERATURE | 1995 | 247 | 54 | 28% |
Role of Haloperidol in Palliative Medicine: An Update | 2012 | 10 | 33 | 36% |
Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5 '-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia | 2002 | 24 | 20 | 75% |
PLASMA-LEVEL MONITORING OF ANTIPSYCHOTIC-DRUGS CLINICAL UTILITY | 1986 | 106 | 100 | 91% |
Sensitive detection of haloperidol and hydroxyzine at multi-walled carbon nanotubes-modified glassy carbon electrodes | 2008 | 9 | 15 | 40% |
Pharmacokinetics of haloperidol - An update | 1999 | 91 | 182 | 34% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | HARVEY W PETERS STUDY PARKINSONS DIS DISORD | 2 | 50% | 0.2% | 3 |
2 | OCTSPAN | 1 | 100% | 0.1% | 2 |
3 | PSYCHIAT NEUROPSYCHIAT UNIT | 1 | 50% | 0.1% | 2 |
4 | COCHRANE IZOPHRENIA GRP | 1 | 13% | 0.6% | 9 |
5 | CONTINUING PSYCHIAT SERV IZOPHRENIA RELATED | 1 | 50% | 0.1% | 1 |
6 | ESTEEM | 1 | 50% | 0.1% | 1 |
7 | FERNAND SEQUIN | 1 | 50% | 0.1% | 1 |
8 | KLIN POLIKLIN PSYCIAT PSYCHOTHER IE | 1 | 50% | 0.1% | 1 |
9 | KYUSHU S | 1 | 50% | 0.1% | 1 |
10 | BIPOLAR PSYCHIAT DISORDERS PROGRAM | 0 | 33% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000191323 | COCHRANE IZOPHRENIA GRP//WARM SUPPLEMENTING KIDNEY YANG//SURG DEV SCI |
2 | 0.0000123180 | PALIPERIDONE PALMITATE//LONG ACTING RISPERIDONE//OLANZAPINE PAMOATE |
3 | 0.0000115478 | PHVA//PLASMA HOMOVANILLIC ACID//HOMOVANILLIC ACID |
4 | 0.0000105545 | PHENOTHIAZINE DRUGS//CHLORPROMAZINE HCL//PROMETHAZINE HYDROCHLORIDE |
5 | 0.0000092418 | ACUTE AGITATION//INHALED LOXAPINE//INTRAMUSCULAR HALOPERIDOL |
6 | 0.0000083559 | PAINFUL LEGS AND MOVING TOES//MOVING TOES//PAINFUL LEGS |
7 | 0.0000083122 | CLOZAPINE//RISPERIDONE//OLANZAPINE |
8 | 0.0000081062 | ANTIPSYCHOTIC POLYPHARMACY//POLYPHARMACY//TUNKU ABDUL RAHMAN NEUROSCI |
9 | 0.0000078596 | 9 HYDROXYRISPERIDONE//NORCLOZAPINE//PALIPERIDONE |
10 | 0.0000072720 | CLINICAL GLOBAL IMPRESSIONS SCALE//FUNCTIONAL REMISSION//SYMPTOMATIC REMISSION |